Approximately 1% of women in the United States will be diagnosed with epithelial ovarian
cancer (EOC) during their lifetime. It is most likely to present at a more advanced stage …

Epithelial ovarian cancer (EOC) is usually diagnosed late at an advanced stage. Though
EOC initially responds to treatment, the recurrence rate is pretty high. The efficacy of different …

Latest clinical evidence of maintenance therapy in ovarian c... : Current Opinion in Obstetrics
and Gynecology Latest clinical evidence of maintenance therapy in ovarian cancer : Current …

Abstract Purpose of Review Advanced epithelial ovarian cancer remains the most lethal
gynaecological cancer. Most patients with advanced disease will relapse within 3 years after …

PARP inhibitors (PARPi) have shown have activity in the treatment of ovarian cancer.
Previous studies documented activity in patients with germline (gBRCA) and tumor (tBRCA) …

Notwithstanding continuing efforts to improve the primary treatment for ovarian cancer, most
patients will ultimately develop recurrent disease. The benefits of detection and early …

Introduction Seventy-five percent of ovarian cancer would relapse within 18–28 months after
platinum-base chemotherapy. Evidence suggests that maintenance chemotherapy is …

Background Ovarian cancer remains the most deadly gynecologic cancer with the majority
of patients relapsing within 3 years of diagnosis. Traditional treatment paradigms linked to …

Epithelial ovarian cancer has a very high rate of relapse after primary therapy; historically
approximately 70% of patients with a complete clinical response to surgery and adjuvant …

Most women with advanced ovarian cancer respond to initial treatment, consisting of
surgical resection and≈ 6 cycles of platinum-based chemotherapy. However, disease …